Lievano, G <br/><br/>
Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.  [electronic resource] 

 -  Methods and findings in experimental and clinical pharmacology  May 1997 
 - 261-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0379-0355 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Biomarkers, Tumor<br/>Cytosine--analogs & derivatives<br/>Down-Regulation<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Injections, Intraperitoneal<br/>Male<br/>Neoplasm, Residual--drug therapy<br/>Proliferating Cell Nuclear Antigen--drug effects<br/>Prostatic Neoplasms--drug therapy<br/>Rats<br/>Rats, Inbred F344<br/>Transforming Growth Factor beta--drug effects<br/>Tumor Cells, Cultured